Emmaus Life Sciences, Inc. (EMMA): R&D Expense
$313.0K
Year ended 2025-12-31
$237.0K
Trailing 12 months to 2026-06-30
-43.4%
3-year compound annual growth
-33.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $313.0K | -52.4% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $657.0K | -44.7% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $1.19M | -31.1% | 2025-04-14, From 2023-01-01 |
| 2022-12-31 | $1.73M | -58.0% | 2024-07-03, From 2022-01-01 |
| 2021-12-31 | $4.11M | +70.7% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $2.41M | +10.3% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $2.18M | +26.7% | 2021-08-10, From 2019-01-01 |
| 2018-12-31 | $1.72M | n/a | 2021-01-25, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $313.0K | -52.4% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $94.30M | -20.1% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $74.04M | +15.3% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $44.49M | +11.3% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $24.97M | +50.9% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $122.0K | +3.4% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $73.70M | +25.4% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $25.24M | -53.3% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $30.81M | +14.8% |
Compare EMMA, PRLD, EVMN, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗